Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Contineum Therapeutics, Inc. on June 26, 2026. The meeting was conducted virtually. As of the record date of April 27, 2026, there were 32,723,877 shares of Class A common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Proposal 1: Election of Directors
Stockholders elected three Class II directors to serve until the 2029 Annual Meeting. The voting results were as follows:
| Director Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Evert Schimmelpennink | 21,773,559 | 131,384 | 6,133,812 |
| Lori M. Lyons-Williams | 20,593,715 | 1,311,228 | 6,133,812 |
| Diego Miralles, M.D. | 21,673,187 | 231,756 | 6,133,812 |
Proposal 2: Ratification of Auditors
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows:
| Votes For | Votes Against | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| 28,021,047 | 16,104 | 1,604 | N/A |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the three newly elected directors and their term expiration in 2029.
- Verification of the significant number of broker non-votes (6,133,812) on the director election, indicating shares held by brokers without voting instructions.
- Confirmation that Ernst & Young LLP remains the independent auditor for the 2026 fiscal year.
- Review of the company's financial status in subsequent filings, as this 8-K contains no financial data.